ImmPACT designs logic gated CARs to address specific challenges in hematological and solid tumors.

Scientific approach

Developing cutting-edge CAR-T platform technologies to address antigen escape, ‘on-target, off-tumor’ toxicities and immunosuppressive microenvironment, all key challenges of current cell therapies in oncology.

link to ImmPACT-Bio page


Solid and hematological tumors


Sumant Ramachandra, MD, PhD – CEO

Scroll to top